| Stage | REGN | % of rev | LLY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $5.1B | 100.00% | $24.4B | 100.00% | LLY ×4.77 |
| Gross profit | $4.5B | 88.79% | $20.5B | 83.88% | REGN +4.9pp |
| Operating income | $2.0B | 40.04% | $8.6B | 35.28% | REGN +4.8pp |
| Pre-tax income | $2.3B | 44.65% | $8.4B | 34.46% | REGN +10.2pp |
| Net income | $1.9B | 38.09% | $6.5B | 26.44% | REGN +11.7pp |
| Stage | REGN | LLY | Gap · A − B |
|---|---|---|---|
| Revenue | $5.1B100.00% | $24.4B100.00% | LLY ×4.77 |
| Gross profit | 88.79%$4.5B | 83.88%$20.5B | REGN +4.9pp |
| Operating income | 40.04%$2.0B | 35.28%$8.6B | REGN +4.8pp |
| Pre-tax income | 44.65%$2.3B | 34.46%$8.4B | REGN +10.2pp |
| Net income |
| 38.09%$1.9B |
| 26.44%$6.5B |
| REGN +11.7pp |
REGN · IMRX 10-KMar 6 '26
“In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in a planned clinical trial of patients with unresectable or metastatic RAS-mutant non-small cell lung cancer.”
LLY · IMRX 10-KMar 6 '26
“In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed on prior therapy.”